News
May 23, 2011

HRSA Issues Proposed Rule on Exclusion of Orphan Drugs for Certain Covered Entities Under the 340B Program

Arnold & Porter Advisory
By John Gould Jeffrey L. Handwerker Kristin M. Hicks Rosemary Maxwell
Find more content tagged:

People

John Gould
John Gould
Partner
Washington, DC
+1 202.942.6281
Email
VCard
Jeffrey L. Handwerker
Jeffrey L. Handwerker
Partner
Washington, DC
+1 202.942.6103
Email
VCard
Kristin M. Hicks
Kristin M. Hicks
Partner
Washington, DC
+1 202.942.5846
Email
VCard
Rosemary Maxwell
Rosemary Maxwell
Counsel
Washington, DC
+1 202.942.6040
Email
VCard

Related Content

July 31, 2020
Update: Regulation for COVID-19 clinical trials conducted with medicinal products containing or consisting of GMOs has now been adopted
BioSlice Blog
Subscribe
Subscribe Link

Email Disclaimer

Reject Accept